FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 812 - Board of Scientific Counselors Deputy Director for Infectious Diseases - Authorized by Law

GENERAL INFORMATION

Committee Name	Board of Scientific Counselors Deputy Director for Infectious Diseases	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	812
Original Establishment Date	11/17/1962	Committee Status	Terminated
Actual Termination Date	4/1/2025	Committee URL	https://www.cdc.gov/bscid
Actual Merged Date		Presidential Appointments*	No
New Committee This FY	No	Max Number of Members*	17
Terminated This FY	Yes	Designated Fed Officer Position Title*	Senior Advisor, National Center for Emerging and Zoonotic Infectious Diseases, CDC
Merged This FY		Designated Federal Officer Prefix
Current Charter Date	10/31/2023	Designated Federal Officer First Name*	Sarah
Date Of Renewal Charter	10/31/2025	Designated Federal Officer Middle Name	D.
Projected Termination Date	3/31/2025	Designated Federal Officer Last Name*	Wiley
Exempt From Renewal*	No	Designated Federal Officer Suffix	MPH
Specific Termination Authority	E. O. 14217	Designated Federal Officer Phone*	(404) 639-4840
Establishment Authority*	Authorized by Law	Designated Federal Officer Fax*
Specific Establishment Authority*	42 U.S.C. 217a	Designated Federal Officer Email*	swiley@cdc.gov
Effective Date Of Authority*	11/17/1962
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Scientific Technical Program Advisory Board

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Terminate
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	The Board provides critical advice and direction to the Secretary, Department of Health and Human Services (HHS), the CDC Director, and CDC’s infectious disease national centers on improving the Agency’s efforts to prevent and control infectious diseases. The Board comprises a highly respected and diverse group of nationally and internationally recognized experts, who bring extensive experience to help CDC ensure sound public health policies and programmatic balance for current and emerging infectious disease threats. Their candid advice and critiques help to improve program focus and maximize program effectiveness. Over many years, the Board has provided valuable advice to CDC for strengthening public health capacity at national, state, and local levels; enhancing preparedness to address new diseases and public health challenges; developing new tools for detecting and controlling infectious diseases; and implementing science-based programs to prevent the spread of infectious diseases. The Board's global scientific expertise plays an integral role in helping CDC's infectious disease programs stay abreast of current health trends and appropriate scientific directions, thereby ensuring the highest quality prevention and control efforts.
How is membership balanced?*	The Board consists of up to 17 public members, including the Chair. Members are selected by the Secretary from authorities knowledgeable in the fields relevant to the issues addressed by the infectious disease national centers (e.g., respiratory diseases, healthcare-associated infections, antimicrobial resistance, foodborne diseases, zoonotic and vector-borne diseases, sexually transmitted diseases, preparedness) and related specialties, including clinical and public health practice (including state and local health departments), laboratory practice, research, diagnostics, microbiology, immunology, molecular biology, bioinformatics, infectious disease modeling and outbreak analytics, health policy/communications, and industry. A variety of sources are used to identify qualified, diverse candidates for the Board. In addition to the broad professional expertise, a diverse membership, including the geographical location of members, helps to ensure that the committee provides a well-balanced perspective.
How frequent & relevant are cmte mtgs?*	In FY 2024 the full Board and its workgroups met less often than in a typical year because several Board and workgroup members had completed their terms of service during the COVID-19 pandemic, and the membership slots had not yet been refilled. The full Board convened once in FY 2024 via webinar in November 2023. Current plans are for two meetings of the full Board in FY 2025. Typically, between meetings, the Board is kept abreast of CDC’s infectious disease activities through periodic emails. None of the Board’s workgroups convened in FY 2024. It is anticipated that the Board’s workgroups will meet in FY 2025 as follows: The FSMA Surveillance Working Group plans to meet twice in FY 2025 to provide input to the Board on challenges with reoccurring, emerging, and persisting (REP) strains of major pathogens and impacts of culture-independent diagnostic testing to surveillance and solving foodborne illness outbreaks and monitoring for antimicrobial resistance. The AFM Task Force plans to present a final report to the Board in November 2024 and will likely sunset following that meeting. It has shared findings, observations, and outcomes with the Board in two key areas: (1) Acute flaccid myelitis etiologies (AFM) and pathogenesis; and (2) clinical treatment of AFM. The workgroup evaluated new research and identified gaps in knowledge related to pathogenesis and clinical management of AFM and how research activities should be prioritized. In addition, the workgroup has served as an informational network for the Board to discuss the effects of the COVID-19 pandemic on AFM diagnosis, clinical management, and research activities. The Infectious Disease Laboratory Working Group (IDLWG) did not meet in FY 2024; however, it has an updated Terms of Reference as of May 2024, and in FY 2025, its leadership anticipates the group hold 6 virtual meetings to focus on (1) reviewing progress towards integration of advanced molecular detection techniques into public health, and (2) the current and future state of diagnostic testing capabilities. The Board’s newest workgroup, the Wastewater Surveillance Working Group, was established in FY 2024, and it plans to hold 6 virtual meetings in FY 2025, when its discussions will focus on assessing (1) targets for wastewater surveillance that can inform public health action, (2) considerations for determining if community-based or facility-based wastewater testing will best inform public health actions, and (3) the ethical, resource, and other limitations that challenge the use and implementation of wastewater surveillance. The workgroup will report its findings on these topics to the Board at meetings in FY 2025 and beyond.
Why advice can't be obtained elsewhere?*	The Board plays an essential role in assisting CDC and the infectious disease national centers in evaluating programs, setting priorities, and developing and achieving goals. In FY25, the Board and its workgroups will play an important role in helping CDC address several critical public health issues. Examples include providing critical insights regarding wastewater surveillance as a public health tool for infectious disease programs, advances in foodborne illness surveillance, data modernization efforts in CDC’s infectious disease programs, and advances in infectious disease diagnostics. The Board will provide critical information to our infectious disease centers on improving outbreak responses and potential impacts on at risk populations. The Board and its workgroups have significant expertise in these areas that can help CDC best focus resources strategically. The broad infectious disease expertise represented on the Board and centralized in one committee does not exist elsewhere.
Why close or partially close meetings?	N/A
Recommendation Remarks	2025 Secretary Directive-Elimination of Federal Advisory Committees Within the Department of Health and Human Services, Terminated 04.01.2025. EO 14217 Reducing the Scope of the Federal Bureaucracy. Special Government Employees (SGE): Jeffrey Duchin, start date 07/27/2024, and Ilhem Messaoudi, start date 11/10/2020, declined to extend their terms beyond their end date 09/30/2024. Saad Omer, start date 07/28/2022, resigned 10/24/2023. FDA ex officio member Joseph Toerner, start date 03/21/2024, resigned his FDA position 07/31/2024. FDA ex officio member Yodit Belew, start date 09/14/2024.

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	Yes
Outcome Trust In Government	Yes	Action Reallocate Resources	No
Outcome Major Policy Changes	No	Action Issued New Regulations	No
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	No	Action Approved Grants Or Other Payments	No
Outcome Improved Service Delivery	Yes	Action Other	Yes
Outcome Increased Customer Satisfaction	Yes	Action Comment	Established a workgroup to examine issues regarding wastewater surveillance so that resources focus on agency-wide priorities, standardized approaches to wastewater testing and analysis are adopted, where appropriate, and a coordinated approach to guidance about the use of wastewater surveillance is taken to inform public health actions.
Outcome Implement Laws/Reg Requirements	No	Grants Review*	No
Outcome Other	No	Number Of Grants Reviewed	0
Outcome Comment	N/A	Number Of Grants Recommended	0
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$0.00
Cost Savings Comment	The Board’s advice and guidance to CDC’s infectious disease programs could impact cost savings in numerous ways. Through their broad expertise, the members help identify new strategies and opportunities to better target and focus prevention and control efforts. The Board has also been instrumental in helping enhance collaborations across federal organizations and with state and local public health partners.	Grants Review Comment	N/A
Number Of Recommendations*	212	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	In FY2024, 4 recommendations were made to CDC leadership and staff during Board meetings. Because the Board met fewer times in FY2024 than in a typical year and because that meeting focused on 2 specific topics, the Board’s recommendations were focused on establishing a workgroup on wastewater surveillance and on completing the required report to the HHS Secretary on foodborne illness surveillance.	Access Agency Website	Yes
% of Recs Fully Implemented*	32.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	No change in FY2024.	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	68.00%	Access Publications	Yes
% of Recs Partially Implemented Comment	No change in FY2024.	Access Other	No
Agency Feedback*	Yes	Access Comment	The full minutes of each Board meeting, which includes summaries of workgroup meetings, are posted on CDC's website.
Agency Feedback Comment*	The agency provides feedback to the public at each Board meeting through CDC staff and leadership updates on previous recommendations received from the full Board or suggestions from individual Board members and from the working groups. Feedback is also provided less formally via email updates. Recommendations and suggestions by Board members are also regularly categorized and presented to CDC leadership.	Narrative Description*	The Board provides critical advice and direction to the Secretary, Department of Health and Human Services (HHS), the CDC Director, and CDC’s infectious disease national centers on improving the Agency’s efforts to prevent and control infectious diseases. The Board comprises a highly respected and diverse group of nationally and internationally recognized experts, who bring extensive experience to help CDC ensure sound public health policies and programmatic balance for current and emerging infectious disease threats. Their candid advice and critiques help to improve program focus and maximize program effectiveness. Over many years, the Board has provided valuable advice to CDC for strengthening public health capacity at national, state, and local levels; enhancing preparedness to address new diseases and public health challenges; developing new tools for detecting and controlling infectious diseases; and implementing science-based programs to prevent the spread of infectious diseases. The Board's global scientific expertise plays an integral role in helping CDC's infectious disease programs stay abreast of current health trends and appropriate scientific directions, thereby ensuring the highest quality prevention and control efforts. The Board consists of up to 17 public members, including the Chair. Members are selected by the Secretary from authorities knowledgeable in the fields relevant to the issues addressed by the infectious disease national centers (e.g., respiratory diseases, healthcare-associated infections, antimicrobial resistance, foodborne diseases, zoonotic and vector-borne diseases, sexually transmitted diseases, preparedness) and related specialties, including clinical and public health practice (including state and local health departments), laboratory practice, research, diagnostics, microbiology, immunology, molecular biology, bioinformatics, infectious disease modeling and outbreak analytics, health policy/communications, and industry.

COSTS

1. Payments to Non-Federal Members*		1. Est Paymnts to Non-Fed Membrs Nxt FY*	$0.00
2. Payments to Federal Members*		2. Est. Payments to Fed Members Next FY*	$0.00
3. Payments to Federal Staff*		3. Estimated Payments to Federal Staff*	$0.00
4. Payments to Consultants*		4. Est. Payments to Consultants Next FY*	$0.00
5. Travel Reimb. For Non-Federal Membrs*		5. Est Travel Reimb Non-Fed Membr nxtFY*	$0.00
6. Travel Reimb. For Federal Members*		6. Est Travel Reimb For Fed Members*	$0.00
7. Travel Reimb. For Federal Staff*		7. Est. Travel Reimb to Fed Staf Nxt FY*	$0.00
8. Travel Reimb. For Consultants*		8. Est Travel Reimb to Consltnts Nxt FY*	$0.00
10. Other Costs		10. Est. Other Costs Next FY*	$0.00
11. Total Costs	$0.00	11. Est. Total Next FY*	$0.00
Date Cost Last Modified	3/14/2025 9:33 AM	Est. Fed Staff Support Next FY*	0.00
Federal Staff Support (FTE)*		Est Cost Remarks	The Committee was terminated effective March 31, 2025, under E.O. 14217, Commencing the Reduction of the Federal Bureaucracy.
Cost Remarks

Interest Areas

Category Area Agriculture Agriculture Animals Fish and Wildlife Veterinary Medicine Basic Science Microbiology Computer Technology Technology Information Technology Data Data Quality Federal Employment Federal Employees and Personnel Food and Drugs Biotechnology Food and Drugs Medical Devices Government Federal Government Internal Federal Government State Government Tribal Government Health Biodefense Health Care Hospitals Medical Education Public Health Treatment Land National Parks, Sites, Trails, Recreational Areas Monuments Medicine Diseases Health and Health Research Illnesses Research Basic Research Research and Development Science and Technology Science and Technology Social Sciences Risk Communication Water Water Use

Custom Links

Committee Level Reports